MedTech MetroAdd to calendar
Wednesday, February 24, 2016
5:30 pm – 9:00 pm
Location: Loeb & Loeb, 345 Park Ave, New York, NY 10154
MedTech Metro is an intimate forum and networking series designed to showcase New York’s bioscience and medical technology (Bio/Med) community before an audience of investors, business leaders and healthcare providers committed to promoting and supporting the Bio/Med industry.
5:30 - 6:30 - Registration / Networking Reception
6:30 - 7:15 - Company Presentations
Celf Technologies - The CELF™ wearable sensor generates medical-grade ECG measurement and thus superbly-accurate heart rate, in contrast to simple and often inaccurate pulse monitoring as used by widely established brands such as Fitbit® and Apple®. CELF's technology seamlessly measures and displays key cardiovascular data in real time to let users determine and train in their Dynamic Training Zone™. With CELF, the guess work is removed and the automation of one's real-time, ultra-accurate readings begins. Train for weight loss, cardiovascular conditioning, multiple sports (including swimming), or even Mindfulness. It’s safe, accurate, and passive. Additional sought-after features include body hydration monitoring, skin temperature, and respiration.
Phosplatin Therapeutics - Founded in 2010, Phosplatin Therapeutics is a private, clinical-stage company developing its lead candidate, PT-112, a novel small molecule platinum agent in oncology therapeutics. The company is currently engaged in a Phase I clinical trial across three U.S. sites, led by the MD Anderson Cancer Center in Houston, Texas. PT-112 has a favorable and differentiated profile of safety and activity with the potential to make a significant impact in numerous cancer treatment settings. Phosplatin Therapeutics is funded by high net worth individuals and family offices.
Smart Pill - The Pop Test companies are creating game changing devices and diagnostics for 3rd parties to commercialize. Pop Test’s SMART PILLS, with their proprietary pill to pill communication technology provide a means to not only prevent overdose, particularly with prescription opiates. But to also prevent counterfeiting and diversion because they are programmed to release their drug contents only to the individuals who should be taking them, in the prescribed quantities. Pop Test Smart Pills answer the greatest concern of the FDA and industry alike. Technological and Regulatory roadmap complete. Strategic relationship with Jabil for high volume manufacturing. Partnering opportunities available for investment and/or acquisition.
7:15 - 8:15 - Panel: M&A Activity
As healthcare organizations continue to face a dynamic industry landscape heavily influenced by healthcare reform, mergers and acquisitions (M&A) have become an avenue for new technology development and revenue while also mitigating costs. This trend of consolidation creates a challenging environment that companies must adapt to. February's MedTech Metro introduces a panel of industry experts that will dive deeper into this trend including speakers from the investor community and those with experiences on both sides of this activity - the acquired and the acquirer.
8:15 - 9:00 - Networking
Thank you to our sponsors!